必贝特-U(688759)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688759 必贝特-U

已收盘 09-09 15:00:00

{"stockData":{"symbol":"688759","market":"SH","secType":"STK","nameCN":"必贝特-U","latestPrice":21.5,"timestamp":1788937200000,"preClose":21.83,"halted":0,"volume":4514358,"delay":0,"changeRate":-0.0151,"floatShares":72000000,"shares":450000000,"eps":-0.3945,"marketStatus":"已收盘","change":-0.33,"latestTime":"09-09 15:00:00","open":21.75,"high":21.89,"low":20.95,"amount":96552800,"amplitude":0.0431,"askPrice":21.5,"askSize":11,"bidPrice":21.49,"bidSize":47,"shortable":0,"etf":0,"ttmEps":-0.3945,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789003800000},"marketStatusCode":5,"adr":0,"adjPreClose":21.83,"symbolType":"stock_kcb","openAndCloseTimeList":[[1788917400000,1788924600000],[1788930000000,1788937200000]],"highLimit":24.01,"lowLimit":19.65,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":450036657,"isCdr":false,"pbRate":6.07,"roa":"--","roe":"--","epsLYR":-0.4,"committee":-0.533469,"marketValue":9676000000,"turnoverRate":0.0627,"status":1,"afterMarket":{"amount":4300,"volume":200,"close":21.5,"buyVolume":0,"sellVolume":900,"time":1788939237746,"indexStatus":"已收盘 09-09 15:30:00","preClose":21.83},"floatMarketCap":1548000000},"requestUrl":"/m/hq/s/688759/","defaultTab":"news","newsList":[{"id":"2630314344","title":"健讯Daily|2025年人均预期寿命已达79.25岁，健康城镇创建大幕拉开","url":"https://stock-news.laohu8.com/highlight/detail?id=2630314344","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630314344?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:26","pubTimestamp":1777335969,"startTime":"0","endTime":"0","summary":"政策动向2025年人均预期寿命已达79.25岁，健康城镇创建大幕拉开4月27日下午，国家卫健委召开新闻发布会，介绍“共建健康城镇，共筑健康防线”有关情况。会上，全国爱卫办常务副主任、国家卫生健康委规划司司长庄宁介绍，一年来，我国深入实施健康中国18个专项行动，聚焦重点人群，强化全生命周期的健康服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721237596.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721237596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4581","BK4550","LU1059921491.USD","LU1997245094.SGD","BK4588","LU2456880835.USD","CSCO","LU1066053197.SGD","LU1506573853.SGD","603259","IE00BZ1G4Q59.USD","BK4533","BK4560","LU0792757196.USD","LU0348723411.USD","LU2102340556.USD","LU1244550494.USD","LU2237443465.HKD","LU1894683264.USD","LU0098860793.USD","IE00BDGV0183.EUR","BK4612","02522","LU1066051225.USD","BK0216","LU1162221912.USD","002653","CSCS","CSCL","LU1244550221.USD","BK0028","LU0823417653.USD","LU1880398554.USD","LU1244550577.SGD","LU1066051811.HKD","LU2328871848.SGD","688759","SG9999015945.SGD","LU0889566641.SGD","IE00BFXG1179.USD","LU1599440770.SGD","SG9999015978.USD","LU2237443978.SGD","LU1674673428.USD","LU0950375773.USD","LU1969619763.USD","LU1934453819.USD","IE00B42XCP33.USD","300026","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619195462","title":"必贝特(688759.SH)：注射用盐酸伊吡诺司他获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619195462","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2619195462?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:24","pubTimestamp":1773397472,"startTime":"0","endTime":"0","summary":"智通财经APP讯，必贝特 发布公告，近日，公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意注射用盐酸伊吡诺司他联合CHOP方案在初治外周T细胞淋巴瘤患者中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608826766","title":"必贝特(688759.SH)：BEBT-701临床试验申请获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608826766","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2608826766?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:00","pubTimestamp":1770109241,"startTime":"0","endTime":"0","summary":"智通财经APP讯，必贝特 发布公告，近日，公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司自主研发的全球首创AGT/PCSK9双靶点小干扰核酸药物BEBT-701开展用于治疗轻中度高血压合并低密度脂蛋白胆固醇升高的I-II期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"必贝特(688759.SH)：BEBT-701临床试验申请获得国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601533894","title":"宜明昂科与Axion“分手”；江西省卫健委党组书记被查","url":"https://stock-news.laohu8.com/highlight/detail?id=2601533894","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2601533894?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:41","pubTimestamp":1767832919,"startTime":"0","endTime":"0","summary":"政策动向国家药监局：优化临床急需境外已上市药品审评审批央视新闻消息显示，为加快临床急需境外已上市药品在境内上市，满足患者临床用药迫切需求，国家药监局进一步优化这类药品审评审批。国家药监局表示，坚持以临床价值为导向，鼓励申请人在中国开展全球同步研发、同步申报上市；鼓励临床急需境外已上市的原研药及仿制药在境内申报，对于符合要求的可纳入优先审评审批范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601083612141760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601083612141760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU2148510915.USD","BK0188","600276","LU1655091616.SGD","LU2289578879.USD","LU2488822045.USD","LU1820825898.SGD","BK0028","LU0405327494.USD","LU1997245177.USD","688321","LU2097828474.EUR","LU1064130708.USD","BK0239","BK0096","LU1781817850.SGD","LU2097828557.USD","LU2328871848.SGD","LU1146622755.USD","LU2097828631.EUR","BK0236","LU1997245094.SGD","LU2495084118.USD","LU1969619763.USD","688759","LU1064131003.USD","LU1328615791.USD","BK0046","LU2097828805.USD","BK0060","300653","LU1580142542.USD","BK0251","LU2580892862.HKD","002173","LU0405327148.USD","LU1255011170.USD","LU1997244956.HKD","BK0077","BK0114","LU2097828714.EUR","LU2580892789.USD","BK0183","BK0012"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788991185069,"stockEarnings":[{"period":"1week","weight":-0.0917},{"period":"1month","weight":-0.1644},{"period":"3month","weight":-0.2612},{"period":"6month","weight":-0.4518},{"period":"1year","weight":0.2092},{"period":"ytd","weight":-0.2602}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0038},{"period":"3month","weight":-0.0089},{"period":"6month","weight":-0.0351},{"period":"1year","weight":0.0379},{"period":"ytd","weight":-0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州必贝特医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10687人(较上一季度减少2.91%)","perCapita":"6737股","listingDate":"2025-10-28","address":"广东省广州市黄埔区高新技术产业开发区科学城崖鹰石路25号A-3栋第八层802房","registeredCapital":"45003万元","survey":"　　广州必贝特医药股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是注射用盐酸伊吡诺司他（BEBT-908，商品名：贝特琳®）、BEBT-209、BEBT-109、BEBT-503、BEBT-809、BEBT-507、BEBT-701、其他小核酸药物。","listedPrice":17.78},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"必贝特-U(688759)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供必贝特-U(688759)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"必贝特-U,688759,必贝特-U股票,必贝特-U股票老虎,必贝特-U股票老虎国际,必贝特-U行情,必贝特-U股票行情,必贝特-U股价,必贝特-U股市,必贝特-U股票价格,必贝特-U股票交易,必贝特-U股票购买,必贝特-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"必贝特-U(688759)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供必贝特-U(688759)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}